Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension

Trial Profile

EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Riociguat (Primary) ; Anticoagulants; Vitamin K antagonists
  • Indications Pulmonary arterial hypertension; Pulmonary hypertension
  • Focus Adverse reactions
  • Acronyms EXPERT
  • Sponsors Bayer
  • Most Recent Events

    • 11 Feb 2022 Results of patients with chronic thromboembolic pulmonary hypertension receiving a vitamin K antagonist or a non-vitamin K antagonist oral anticoagulant at baseline,published in the Journal of Heart and Lung Transplantation
    • 20 May 2020 Results presented at the 116th International Conference of the American Thoracic Society
    • 20 May 2020 Results (n=1282) assessing patients with PAH or CTEPH receiving riociguat in combination with prostanoids at baseline presented at the 116th International Conference of the American Thoracic Society
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top